Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alto Neuroscience, Inc. Common Stock
(NY:
ANRO
)
17.27
+0.25 (+1.47%)
Streaming Delayed Price
Updated: 2:45 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alto Neuroscience, Inc. Common Stock
< Previous
1
2
Next >
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen)
↗
January 15, 2026
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
December 26, 2025
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via
Chartmill
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
↗
November 17, 2025
Via
Benzinga
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
November 17, 2025
Via
Benzinga
Alto Neuroscience Inc (NYSE:ANRO) Reports Narrower Q3 2025 Loss and Accelerated Pipeline Progress
↗
November 12, 2025
Alto Neuroscience reports a narrower-than-expected Q3 2025 loss and advances its precision psychiatry pipeline, with cash extending into 2028.
Via
Chartmill
These stocks are moving in today's session
↗
October 20, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 20, 2025
Via
Benzinga
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session.
↗
October 20, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Gapping stocks in Monday's session
↗
October 20, 2025
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 03, 2025
Via
Benzinga
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug
↗
October 03, 2025
FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
Via
Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 02, 2025
Via
Benzinga
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
↗
September 29, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...
Via
Benzinga
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
September 29, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...
Via
Benzinga
Alto Neuroscience Posts Q2 Net Loss
↗
August 13, 2025
Via
The Motley Fool
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
↗
June 03, 2025
Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207.
Via
Benzinga
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock
↗
March 03, 2025
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.
Via
Stocktwits
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
December 16, 2024
Via
Benzinga
Nasdaq Down 2%; US Crude Stocks Increase
↗
October 23, 2024
Via
Benzinga
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
↗
October 23, 2024
Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies.
Via
Benzinga
Gold Moves Lower; AT&T Earnings Top Views
↗
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 23, 2024
Via
Benzinga
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
↗
October 23, 2024
Via
Benzinga
Topics
Stocks
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 23, 2024
Via
Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
↗
October 23, 2024
Via
Benzinga
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024
↗
August 13, 2024
ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
↗
June 10, 2024
Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors.
Via
InvestorPlace
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024
↗
May 14, 2024
ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
↗
April 23, 2024
Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia.
Via
Benzinga
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
